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ABSTRACT
Background Congenital insensitivity to pain (CIP) is a
rare extreme phenotype characterised by an inability to
perceive pain present from birth due to lack of, or
malfunction of, nociceptors. PRDM12 has recently been
identiﬁed as a new gene that can cause CIP. The full
phenotype and natural history have not yet been
reported.
Methods We have ascertained ﬁve adult patients and
report their clinical features.
Results Based on our ﬁndings, and those of previous
patients, we describe the natural history of the PRDM12-
CIP disorder, and derive diagnostic and management
features to guide the clinical management of patients.
Conclusions PRDM12-CIP is a distinct and
diagnosable disorder, and requires speciﬁc clinical
management to minimise predictable complications.
INTRODUCTION
Pain is a sensory modality present in all complex
organisms and used to detect potential and real tissue
damage.1 2 Although it is an unpleasant sensory and
emotional experience, it substantially affects our
behaviour, providing a survival advantage.3
Normally, pain is detected by a complex system
of mechanical and chemical sensors called nocicep-
tors, which then send information through spinal
interneuronal pathways to the brain.4 5 However,
in a number of rare conditions, components of the
pain-signalling pathway may be impaired or fail to
develop.6 One such condition is congenital insensi-
tivity to pain (CIP), where individuals are unable to
perceive pain from birth.7
There are two common forms of CIP. First,
loss-of-function mutation in the SCN9A renders
nociceptors unable to respond to any noxious
stimulus.8 Second, loss-of-function mutation in the
NTRK1 leads to a failure of nociceptors to
develop.9 Recently, a new form of CIP has been
described, caused by mutations in an epigenetic
regulator PRDM12.10 11 The phenotype of these
patients was brieﬂy annotated in the initial study.
Here, we describe the clinical features of ﬁve adult
patients with PRDM12-CIP, derive diagnostic cri-
teria for this speciﬁc form of CIP and suggest man-
agement guidelines.
METHOD
We studied ﬁve adults diagnosed with a
PRDM12-CIP. Four were male and one female, and
their ages were 23, 30, 42, 44 and 57 years. Four of
the ﬁve were from different branches of the same
consanguineous family; two siblings and two cousins.
All had homozygous mutations that had been proven
to be pathogenic, missense or expansion of the
C-terminal PRDM12 polyalanine tract.10 Research
ethics approval had been granted for the study.
Each of the ﬁve adult patients was seen by one of
the authors, a history and pedigree taken, examin-
ation performed, their physician contacted and
medical notes scrutinised. Subsequently, we con-
ducted a detailed telephone interview using a quali-
tative interview questionnaire, see online
supplement. On both occasions, the patients were
either seen with their parents, or had discussed the
relevant questions with their parents. Prior to con-
ducting the interview, informed consent was
obtained for the study from all ﬁve adult patients.
The set of questions were then administered
through a phone interview, see online supplement.
RESULTS
Here, we describe the key clinical features of
patients with PRDM12-CIP, and the corresponding
implications for diagnosis and management. As
four of the individuals had the same mutation, the
consistency of phenotypic features may be
overestimated.
Insensitivity to pain
In keeping with the phenotype of CIP, all indivi-
duals are unable to sense acute pain or chronic
pain. While this was present from birth, CIP was
only diagnosed after the age of three. Due to their
inability to sense pain, all ﬁve individuals have sus-
tained a large number of unusual self-inﬂicted
injuries. Three individuals had lost their tongue tip
due to autoamputation in childhood as well as
injuries to their lips, tongue, gums and the inside of
their cheeks.12 Three individuals had sustained
fractures of the upper and lower limbs.
However, unlike SCN9A and NTRK1 CIP,
patients with PRDM12 mutations could experience
non-global pain insensitivity. In one individual
insensitivity was restricted to their limbs and head;
in another individual pain insensitivity was com-
plete in the left leg, but partial in the right.
Other pain-related features
Staud proposed that individuals who are insensitive
to pain might be deﬁcient in multiple different
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components of the ‘pain’ experience.13 PRDM12-CIP indivi-
duals were able to taste types of food that are commonly asso-
ciated with a painful sensation; being able to recognise spicy
foods as being ‘hot’. They were able to feel a full normal range
of emotions, including painful emotions. SCN9A and NTRK1
CIP individuals are also able to recognise a hot taste and to feel
emotional pain.
Normal neurological examinations and intellect
All ﬁve individuals were of normal intellect and had a normal
neurological examination, including ﬁne touch, deep touch,
pressure, vibration and sensation of itch and tickle. Olfaction
was also normal, in contrast to the anosmia of individuals with
SCN9A CIP.14
Temperature sensing and thermoregulation
All individuals reported being able to sense gross temperature
differences/ranges (separate to their inability to recognise
painful extremities of temperature). However, they were unable
to identify noxious stimuli—for example, if food was too hot—
and thus at risk of heat or cold injuries. Four individuals
reported normal sweating and normal thermoregulation. One
individual could not sense ambient temperature, and so had
encountered difﬁculties with hyperthermia and hypothermia. A
clinically signiﬁcant inability to sense temperature is also a
feature in NTRK1 CIP, but temperature sensing is normal in
SCN9A CIP.
Corneal abrasions due to lack of tear production
All individuals reported impaired tear production, and on exam-
ination had an absent corneal reﬂex. This resulted in a signiﬁ-
cantly increased risk of corneal injuries, and thence keratitis and
corneal scarring—more so than any other form of CIP. Two
individuals had no useful vision in one eye, and in one multiple
corneal grafts had failed.
Recurrent infection
All individuals reported recurrent infections with unknown
causes and sudden onset overnight. These tend to occur in their
feet and hands, and there was no obvious accident or cause for
these infections that the individuals could recall. One required a
below-knee amputation of his right leg to treat a serious
ongoing chronic infection that had not responded to therapies.
Another developed a paraspinal abscess that required surgical
intervention for its resolution. Infections were not painful, and
inﬂammation was always far less than expected by doctors. All
had lost terminal digits through minor injuries becoming chron-
ically infected, and then progress to osteomyelitis, which was
often only treatable by amputation. Interestingly, none had suf-
fered from septicaemia or pneumonia. Staphylococcus aureus
caused all signiﬁcant infections.
Deleterious mutations of another gene associated with a pain-
less phenotype, NTRK1, are also associated with recurrent
S. aureus infections. NGFβ-TRKA signalling has been found to
have a role in innate immune signalling.15 Why PRDM12-CIP
should predispose individuals to recurrent infections is unknown.
Charcot’s joints
Surprisingly, none of the individuals described were thought to
have signiﬁcant Charcot’s joints, either by symptoms or by
radiographic examination. Why this should be is puzzling, as all
individuals with SCN9A and NTRK1 CIP will have at least one
Charcot’s joint by mid teenage years, and have multiple affected
joints after the age of 20 years.16
DISCUSSION: DIAGNOSIS AND MANAGEMENT
Considering CIP as a diagnosis
CIP should be considered as a diagnosis in any child presenting
with a history of poor or absent responses to painful stimuli.
CIP often presents with unexplained oral injuries (especially
NTRK1 and PRMD12 CIP), unexplained burns, bruises, frac-
tures and joint injuries; as described in the Results. External
examination may reveal an excess of injuries, and there is a
potential for confusion with neglect and with child abuse.
A simple pressure test (pen pressed onto the nail bed with
5–10 kg force) will usually reveal those who feel no pain, by the
lack of a withdrawal response.
Neurological examination is normal, but skin biopsy (seeking
a loss of bare nerve termini in the epidermis) or nerve biopsy
(seeking the deﬁciency of small myelinated nerve ﬁbres unique
to this condition) can be diagnostic, but is uncommon in
current clinical practice.
Distinguishing PRDM12-CIP
Of the possible genetic causes of CIP, PRDM12-CIP should be
considered if painlessness is congenital, if it is of a non-global
nature (but this is not obligatory, however it is unreported in
other forms of CIP), if intellect is normal, sense of smell is
normal (difﬁcult to test reliably <5 years) and if corneal abra-
sions are detected in excess or at an early age (<8 years).
Table 1 summarises the key clinical features that distinguish
SCN9A, NTRK1 and PRDM12-CIP.
Table 1 Summary of differences between painlessness caused by SCN9A, NTRK1 and PRDM12 mutations
Congenital insensitivity to pain
Congenital insensitivity to pain
with anhidrosis
Gene SCN9A PRDM12 NTRK1
Inheritance Autosomal recessive Autosomal recessive Autosomal recessive
Pain Impaired ability to feel pain
Autonomics Sweat: normal
Lacrimation: normal
Sweat: normal
Lacrimation: reduced
Sweat: anhidrosis, recurrent febrile episodes,
hypothermia in cold
Lacrimation: may be reduced
Cranial nerves Smell: anosmia Smell: normal
Corneal reflexes: may be absent
Recurrent Staphylococcus aureus infections
Smell: normal
Corneal reflexes: may be absent
Recurrent S. aureus infections
Peripheral nerves Inability to sense pain Inability to sense pain Inability to sense pain and temperature
CNS Normal intellect, otherwise normal development Mental retardation, variable
CNS, central nervous system.
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Management of ophthalmological complications
Individuals with PRDM12-CIP appear to have a greater inci-
dence of corneal abrasions than other types of CIP.
Management includes at least yearly ophthalmological assess-
ments, regular use of eye lubricants during the day and at night,
eye protection in windy or dusty conditions and the avoidance
of irritants and chemicals (eg, bleach, onion and fumes).
Management of infections
Patients are at increased risk of repeated Staphylococcal infec-
tions that arise without an obvious external cause, see Results.
The early use of topical antibacterial creams until all signs of
inﬂammation or infection have resolved was reported to be
highly effective in preventing chronic infection. For more sig-
niﬁcant infections, the lack of pain as a sign had hindered the
diagnosis of osteomyelitis and septic arthritis, and all involved
physicians should be aware of this. Most signiﬁcant infections
were complicated and required a course of IV antibiotics before
they resolved.
Management of injuries
As patients with CIP are unable to feel pain, this impairs their
ability to detect injuries promptly and appropriately immobilise
the injury to allow for healing. To encourage prompt detection
of injuries, patient/parents should conduct daily self-checks par-
ticularly of vulnerable regions such as their feet, hands and
joints. The medical management of any injuries is as for other
forms of CIP. Currently, an annual MRI skeletal survey is not
recommended for PRDM12-CIP, whereas it is in SCN9A CIP,
because of the lack of proven Charcot’s joints in PRDM12.
CONCLUSION
PRDM12-CIP is a phenotypically distinct form of ‘Congenital
Insensitivity to Pain’; early evidence of corneal scarring, the
preservation of some pain sensing in some individuals, normal
intelligence, a normal sense of smell and sweating being present
(although reduced compared with unaffected siblings).
Management is lifelong with the parents, and later the individ-
ual, displaying constant vigilance for signs of corneal damage,
infections (which are usually S. aureus, and must be treated
aggressively) and bone/joint injury.
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